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Study objective: To compare the survival of patients with IPF treated retro-
spectively with corticosteroids alone, to survival of patients treated with
immunosuppressive and corticosteroids combined.
Design: Non-randomized retrospective cohort study.
Setting: Three tertiary centers in Brazil.
Patients: Eighty-two IPF patients were included. The diagnosis was confirmed by
open lung biopsy in 48. Patients received either corticosteroids alone (group I) or
cytotoxic agents in addition to corticosteroids (group II).
Measurements and results: The primary end-point was mortality. Secondary
outcome included longitudinal changes in FVC. Mean age was 6678 years. FVC
was 71717% of predicted. There were 48 deaths during the study period (59%), 44
secondary to respiratory causes. From preliminary univariate analysis, for the group
as a whole, worse survival was found to be associated with FVC%o70% of predicted
(P ¼ 0:004), evidence of disease progression by follow-up FVC measurements
(P ¼ 0:01), and pharmacologic treatment (P ¼ 0:014). Median survival was 25
months for the group I, and 45 months for the group II (Log-Rank ¼ 6.45,
P ¼ 0:01). After adjusting for FVCX70% ando70% of predicted, there was evidence
to indicate that survival was associated with recommended pharmacologic
treatment only in patients with FVCX70% (Log Rank ¼ 6.84, P ¼ 0:009).Elsevier Ltd. All rights reserved.
55438070; fax: +55 11 50448716.
br (C.A.C. Pereira).
ARTICLE IN PRESS
Survival in idiopathic pulmonary fibrosis—cytotoxic agents compared to corticosteroids 341Conclusions: The combination of immunosuppressive agents and prednisone results
in better survival when compared to prednisone alone in patients with IPF. The
benefit seems to occur only in patients with less severe disease, as reflected by
FVCX70%.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a lung disease
of unknown cause with a median survival less than 5
years.1–3 IPF is defined pathologically as usual
interstitial pneumonia (UIP) by open lung biopsy,4
but in many cases the diagnosis can be made by
typical findings on high-resolution computed tomo-
graphy (HRCT) associated with appropriate clinical
and functional findings.4,5
Corticosteroids (CSs) have been the mainstay of
therapy for IPF, but randomized, placebo-con-
trolled trials are lacking, and their value is
debated.2,6,7 Two recent consensus statements4,8
recommend combining prednisone or prednisolone
with either azathioprine or cyclophosphamide as
initial therapy for IPF. Two small prospective studies
support this recommendation.9,10 A Cochrane re-
view on non-CS immunosuppressive treatment of
IPF concluded that the older agents have generally
not been well evaluated.11 A recent study sug-
gested that combined CSs and cyclophosphamide
therapy has no impact on survival in patients with
IPF.12 Expensive anti-fibrotic treatments have been
recently become available, but a large placebo-
controlled trial of interferon gamma-1b in IPF was
disappointing.13
The aim of present study was to compare the
survival of patients with IPF treated retrospectively
with CS alone, to survival of patients treated with
immunosuppressive and CS combined, both cheap
treatments for IPF in underdeveloped countries.Methods
Patients treated between January 1990 and De-
cember 2000 were identified from two centers in
Sa˜o Paulo and from one center in Porto Alegre,
Brazil. At these centers, patients with interstitial
lung diseases are evaluated by a systematic
protocol.Inclusion criteria
All patients included (n ¼ 82) in the study fulfilled
the following criteria:With surgical lung biopsy (n ¼ 48): Pattern of UIP,
defined according of Katzenstein and Myers.14
Surgical lung biopsies were reviewed by two
pathologists experienced in interstitial lung dis-
eases (EMC, RGF).
Without surgical lung biopsy (n ¼ 34)—all criter-
ia should be present:1. Clinical evidence (dyspnea or cough) of UIP
present for at least 3 months with progression
of symptoms, pulmonary function impairment,
or radiographic abnormality. Abnormal pulmon-
ary function studies included evidence of re-
striction or impaired gas exchange (low DLCO,
increased P(A-a)O2, or fall in SpO2 during
exercise). In this report only the changes in
FVC were analyzed in relation to treatment.2. Age 450.
3. Typical HRCT findings of UIP.5,15
Typical bibasilar end-inspiratory crackles (often
described as ‘‘velcro’’ in character) were present
on auscultation of the lungs in 94% of cases, but
were not essential for inclusion in study.
Exclusion criteria
The exclusion criteria (applied to patients with
surgical biopsy or not) were as follows:1. Evidence of a possible cause of UIP, like
hypersensitivity pneumonitis.2. Stable disease for 41 year, as evidenced by
dyspnea absent or unchanged or non-significant
changes in FVC (o 10% and 0.2 L).3. Significant associated COPD, characterized by
FEV1/FVC ratio o65% of predicted.4. Presence of significant centrilobular nodules,
air-trapping, and extensive ground-glass opaci-
ties (X30%) or ground-glass pattern dissociated
from fibrosis areas, middle and upper lobe
predominance, and absence of honeycombing
at HRCT.4
Patients were categorized as non-smokers or as
smokers (current or former smokers).
Changes in pulmonary function tests at 3–6
months were evaluated.
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the discretion of the assistant physicians with CS
alone (group I, n ¼ 26), or with the combination of
CS and immunosuppressive drugs (group II, n ¼ 56).
Patients were not randomized, and medication use
was not blinded to the outcome evaluators (i.e., an
‘‘open-label’’ study), but these were objective
(death and FVC decline).
The dose of prednisone or equivalent was at least
0.5mg/kg/day for 3 consecutive months, followed
by tapering to 10mg given for 1 year or more,
associated or not with immunosuppressive agents
intended to be given for at least 6 months, a time
required for evaluation of response to these
agents.16 The CS used were prednisone (median
dose ¼ 30mg) by mouth, or weekly pulses of
methylprednisolone (median dose ¼ 1 g). The im-
munosuppressive agents used were cyclophospha-
mide (1–2mg/kg/day by oral route, median
dose ¼ 100mg/day or IV each month, median
dose ¼ 750mg) or oral azathioprine (2–3mg/Kg/
day). Median time of treatment was 14 months for
CSs and 12 months for cyclophosphamide.Study endpoints
The primary outcome measure was mortality.
Survival was assessed through September 1, 2003.
Deaths were identified from follow-up, with the
patient’s family or by search of the state death
registry. The cause of death was obtained by review
of the hospital information, death certificates and,
when available, the autopsy reports.
Causes for death were classified into: respirator-
y—when resulting from respiratory failure due to
IPF or complications of IPF or its treatment, like
lung cancer or respiratory infections; others—those
secondary to diseases not related to IPF or its
treatment. Longitudinal physiological assessment
was done by spirometry. The normal values were
those derived for Brazilian population.17 Response
to therapy was defined by changes in FVC over a 3-
to 6-month period. A failure to respond to therapy
was defined as X10% decrease in FVC (or X200-ml
change).4 In the remaining patients the response
was defined as favorable.Statistical analysis
Continuous data are expressed as mean7SD, med-
ian and range. Group comparisons were made using
unpaired t-tests (for normally distributed, contin-
uous variables), Mann–Whitney test (for non-nor-
mally distributed variables), and chi-square
statistics or Fisher exact tests as appropriate (forcomparisons of proportions). Correlations were
calculated by Pearson’s coefficient.
Survival was estimated as the time since specific
therapy to death or the last clinic visit.
Cumulative survival probabilities were estimated
using the Kaplan–Meier method.18 Cox proportional
hazards regression was used to identify variables
associated with survival.19 Variables that were
associated with mortality at Po0:10 in univariate
analysis were included in multivariate models
(SPSS-10). The mortality was examined using
proportional hazards regression, with the inclusion
of percent predicted FVC as a covariate (to control
for the global severity of disease).
A P value o0.05 (two-sided) was considered
statistically significant.
The study was approved by the ethics committee
of all hospitals involved.Results
Enrollment
Eighty-two patients formed the study group, 26 of
whom were treated with CS alone (group I), and 56
with cytotoxic agents, azathioprine (n ¼ 3) or
cyclophosphamide (n ¼ 53) (group II). Thirteen
patients from group I were treated with pulses of
methylprednisolone and 22 patients from group II
were treated with pulses of cyclophosphamide. The
main reason for prescribing cyclophosphamide was
its lower cost.
Forty-eight subjects in this study had open lung
biopsy and fulfilled the clinicopathologic criteria;
the other 34 fulfilled the clinical and HRCT
clinicoradiologic criteria for the diagnosis of IPF.Clinical variables
Baseline patient characteristics are summarized in
Table 1 according to recommended treatment.
Imbalances were apparent between the two groups
for clubbing and number of smokers or former
smokers (both more frequent in group I). Age, sex,
duration of illness, and FVC% were similar between
the two study groups.Survival analysis
The median follow up time was 28.0 months. There
were 48 deaths during the study period (59%): 44
deaths were secondary to respiratory causes, four
from other causes.
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Figure 1 Survival of patients with IPF treated with
immunossupressive agents (n ¼ 56) or corticosteroids
(n ¼ 26).
Table 1 IPF-patient characteristics according to recommended treatment.
Group I CS (n ¼ 26) Group II immunosupressors (n ¼ 56) P value
Sex (M/F) 15/11 31/25 1.00
Age, yr 6678 6578 0.79
Smokers or ex-smokers, n (%) 19/24 (79%) 26/51 (51%) 0.02
Clinical duration of illness, months 23717 (n ¼ 23) 20717 (n ¼ 48) 0.50
FVC, % predicted 68717 (n ¼ 20) 72718 (n ¼ 51) 0.39
Open surgical biopsy 16 (62%) 32 (67%) 0.71
Clubbing, n (%) 15/25 (60%) 19/51 (37%) 0.06
Plus–minus are means7SD.
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group as a whole, shorter survival was found to be
associated with FVC% of predicted (P ¼ 0:004),
evidence of disease progression by follow-up FVC
measurements (P ¼ 0:01), and treatment
(P ¼ 0:014). Median survival was 25 months for
the group treated with CS alone, and 45 months for
the group treated with immunosuppressive agents
(Log-Rank ¼ 6.45, P ¼ 0:01, Fig. 1).
Age, gender, year of treatment, clubbing, smok-
ing status, duration of symptoms, diagnosis by open
lung biopsy and previous use of CS did not correlate
with survival (P40:10). Due to imbalances between
the two groups regarding smoking and clubbing, a
multivariate analysis (Cox, forward stepwise) was
done in 61 patients where all variables were
available, including age, gender, FVC%, smoking
status and treatment to see their influence on
survival. Only treatment (P ¼ 0:05) and FVC%
(P ¼ 0:02) remained significantly associated to
survival.Initial spirometry was done in 71 patients. After
adjusting for FVCX70% and o70% predicted, there
was evidence to indicate that survival was asso-
ciated with recommended pharmacologic treat-
ment only in patients with FVCX70% (Log
Rank ¼ 6.84, P ¼ 0:009): median survival in pa-
tients with FVCX70% was 31 months for the 10
patients in group I and 88 months for the 27
patients in group II; median survival in patients
with FVCo70% was 24 months for the 10 patients in
group I and 33 months for the 24 patients in group
II. These data are shown in Fig. 2.
Changes in FVC
Eighteen patients from group I and 44 from group II
had at least one measurement of FVC after 3–6
months since the beginning of therapy. FVC
declined 25170.31ml in group I compared with
1057230ml in group II (t ¼ 2.05, P ¼ 0:045). Fail-
ure to respond, as measured by X200-ml decrease
in FVC, was seen in 12 (67%) patients in group I,
compared with 11 (25%) of patients in group II
(x2 ¼ 9:50, P ¼ 0:002).Adverse effects
Respiratory or urinary infections were observed in 16
(29%) cases treated with cytotoxic agents compared
to two (8%) cases treated with CSs (x2 ¼ 4:63,
Po0:05). Hemorrhagic cystitis, fatigue and leuco-
penia resulted in treatment stop in six patients
treated with cyclophosphamide. Diabetes mellitus,
complications due to osteoporosis, and CS myopathy
were seen in 11 patients from both groups.Discussion
In this retrospective study, objective benefits were
seen in a group of patients with IPF treated with
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Figure 2 Survival of patients with IPF, separated according initial FVCX70% of predicted oro70% and treatment with
immunossupressive agents or corticosteroids (Log-Rank ¼ 6.84, P ¼ 0:009).
C.A.C. Pereira et al.344immunosuppressive agents and CSs in comparison
to a group treated with CSs alone.Diagnosis
Studies were lung biopsy showing UIP pattern as the
gold standard for diagnosis of IPF, in the absence of
possible secondary causes, have suggested that
HRCT lung scans are highly specific for establishing
the morphologic pattern of UIP,2,5,20 but honey-
combing should be present. In our study all patients
without open lung biopsy had honeycombing in a
typical distribution of UIP.
ATS/ERS had put forward major and minor
criteria for diagnosis of IPF in the absence of a
surgical lung biopsy.4 Age450 yr is described as
minor criteria but in our study patients less than 50
years old without an open lung biopsy were
excluded.
Transbronchial biopsy, a major criteria according
ATS4 to exclude other diseases than IPF, was done in
only 25% of patients of our patients not submitted
to open lung biopsy. However, in a large series,21
transbronchial biopsy showed diagnosis other than
UIP in only 2% of patients with possible IPF.Treatment
The recent ATS/ERS joint statement4 acknowledged
that there is no supportive evidence from well-
conducted, randomized, placebo-controlled clini-
cal trials that combined treatment with CS and
immunosuppressive agents improves survival orquality of life of IPF patients, and serious treat-
ment-related side effects may outweigh any po-
tential benefits of therapy. A Cochrane review on
non-CS immunosuppressive treatment of IPF con-
cludes that the older agents have generally not
been well evaluated.11 Nevertheless, due to para-
digm changes in basic mechanisms of UIP,22 it seems
likely that these older agents will never be
evaluated by large prospective multicenter studies.
Several early studies of patients with IPF cited
responses of 10 to 30% with CS, but these series
failed to classify patients according to histologic
entities or well-defined radiologic criteria.7,23 In a
study from Michigan,2 29 patients with well-defined
IPF were treated with CS only. The survival was less
than 3 years. A recent study12 found similar
mortality rates among untreated patients with
IPF, compared with those treated with a combina-
tion of CS and immunosupressor agents, but it is
difficult to accept the first group as an adequate
control group, since treatment could be avoided
due to stable disease, a finding observed in many
cases, with resultant better prognosis. In our study,
10 patients not treated were excluded; the median
survival exceeded 60 months in these cases. In
Collard’s study,12 lung biopsy was obtained in all
treated patients, but in only 15% of the untreated
patients. The median survival in untreated patients
with lung biopsy showing UIP was around 23 months
only, compared to 56 months of untreated patients
without lung biopsy, suggesting that other diseases
were included in the last group. Cyclophospha-
mide, either given orally or by pulse therapy, has
been used in a number of studies in patients with
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previous treatment with CS had failed. Interpreta-
tion of these studies is difficult. Diagnosis of IPF/
UIP was secure only in one trial.25 Many patients
had a long time of symptoms or FVCo70% pre-
dicted.24,25 Duration of treatment varied but if p6
months was associated with failure.25,27 Long-term
mortality was not evaluated. Functional responses
ranged from 5%25 to 60%.26.
A few randomized therapeutic trials compared CS
with immunosuppressive or cytotoxic agents.9,10,28
Johnson and colleagues10 compared the effect of
prednisolone and cyclophosphamide vs. predniso-
lone alone in pulmonary fibrosis. Life table analysis
suggested better survival in patients in the cyclo-
phosphamide-prednisolone series but this was not
significant. At 3 years, 10 of 22 patients in the
prednisolone only series had died compared with
three of 21 patients in the cyclophosphamide-
prednisolone series. With death or failure of first
treatment regimen as outcome, there was a
significant advantage to the patients having cyclo-
phosphamide-prednisolone. This advantage was
explained in part by the better lung volumes in
this group on admission. This study is further
limited by the inclusion of patients with collagen
vascular disease.
Raghu and colleagues,10 evaluated the efficacy of
azathioprine and prednisone vs. prednisone and
placebo in 27 patients, 23 of whom had IPF
diagnosed by open lung biopsy specimens. Patients
with associated collagen vascular diseases were
excluded. When adjusted for age, the survival
advantage of azathioprine/prednisone became
marginally significant.
Winterbauer28 related a prospective randomized
double-blind placebo-controlled trial of treatment
of IPF in 27 participants, 13 randomized to receive
prednisone and double-blinded placebo and 14 to
receive prednisone and azathioprine. Other clinical
details and diagnostic criteria were not described
in the published study. Mean survival time was 43
months for treatment with prednisone and
azathioprine, with eight survivors at last follow-
up (57%). For prednisone alone it was 34 months
with four survivors (31%).
These figures are similar to our findings.
High-dose intravenous (IV) methylprednisolone
has been used therapeutically in a number of
medical fields to avoid the complications and side
effects of long-term glucocorticoid therapy and
because of the perception that high-dose IV
methylprednisolone may have ‘‘special’’ therapeu-
tic effects. Intermittent high dose ‘‘pulse’’ CS
therapy could inhibit neutrophil accumulation in
IPF29 compared to usual doses. Based on this belief,13 patients in our study were treated with this
regimen, but no difference in survival or FVC
decline was observed in comparison to the other
13 patients treated with oral steroids. Similarly, no
differences in FVC changes were seen between
patients treated with oral and IV cyclophospha-
mide.Functional changes
In our study, patients with FVCp70% predicted had
a shorter survival in comparison to those with
FVC470%. Three recent papers30–32 reported pre-
dictors of survival in a total of 220 well-defined IPF
patients. Latsi and colleagues30 in a retrospective
study of 61 IPF patients indicate that patients with
poorer initial lung function had shorter survivals.
All three studies 30–32 indicated that stabilization
and/or improvement of the FVC% predicted at 6
and again at 12 months was associated with
improved survival. Declines in the FVC% predicted
(410%) predicted shorter survivals.
In our study, in patients with FVCp70% pre-
dicted, the results of treatment with cytotoxic
agents were similar to those seen with CS
alone. Our study also shows that treatment
of IPF with cytotoxic agents and CS result in a
significantly lesser decrease in FVC in comparison
to patients treated with CS alone, with greater
survival.Time of treatment and side effects
While the median follow-up was 28.0 months, the
median time of treatment was 14 months for CSs
and 12 months for cyclophosphamide. The physi-
cians in charge stopped therapy during the course
of the disease for several reasons: side effects
(n ¼ 26), cumulative doses of cyclophosphamide
exceeding 50 g (n ¼ 6), clinical and functional
stability (n ¼ 4) and others (n ¼ 5). In patients
treated with cytotoxic agents the duration of
treatment correlated with survival time (Cox
analysis, P ¼ 0:05). In the present study 44
deaths were secondary to respiratory causes. Some
deaths were ascribed to respiratory infections, but
a clear relation with treatment could not be
established.Limitations
Several possible limitations are present in our
study. Randomized prospective-controlled clinical
ARTICLE IN PRESS
C.A.C. Pereira et al.346trials are considered the gold standard for evalua-
tion of drug therapy; our study is retrospective.
Selection bias is always a possibility in patients
studied in tertiary centers. Many more patients
with possible IPF were seen in our centers during
the period of study, but were not included due to
stringent inclusion criteria. The percentage of
patients submitted to surgical lung biopsy in the
study group was greater than all patients with
possible IPF evaluated in the same time period
(around 25%). Temporal changes occurred in diag-
nostic criteria during the period of study, but we
retrospectively applied uniform criteria for diag-
nosis of IPF. All histologic and HRCT data were
reviewed. There was no evidence of temporal
changes in severity of disease, as evidenced by
lack of correlation between year of diagnosis and
duration of symptoms, FVC and age at diagnosis.
Imbalance between the two groups was present
in some clinical findings. A study33 showed that
survival was extended in patients with IPF who
were cigarette smokers at the time of their initial
evaluation and clubbing was associated to worse
survival. In our study neither smoking status nor
clubbing influenced survival.
We tried eliminating all confounding factors
by: (1) limiting the characteristics of subjects
included and (2) using Cox regression, where the
only factors related to survival were FVC and
treatment group.
Digital clubbing is associated with many unre-
lated serious diseases but its pathogenesis remains
a clinical enigma. It has been hypothesized that
platelet clusters impacting in the distal vasculature
mediate the morphological changes of clubbing.
Since the multifunctional cytokines vascular en-
dothelial growth factor and platelet-derived
growth factor are released on platelet aggregation
and are hypoxically regulated,34 patients with
clubbing could be more hypoxemic and have a
worse prognosis. However, patients with clubbing
had similar exercise saturation (8477%) in compar-
ison to those without clubbing (8576%).Conclusions
From the results of the present study it can be
concluded that the combination of cytotoxic agents
and CSs results in a longer survival time when
compared to CSs alone in patients with IPF. The
benefit seems to occur only in patients with less
severe disease, as reflected by a FVCX70%.
The median survival found in the present study
and in another large series of patients12 treated
with CSs and immunosuppressive agents are verysimilar (45 and 47 months, respectively), so we
suggest that new treatments involving expensive
drugs should be planned to exceed these results in
a significant way.References
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